Novartis announced that it has successfully completed its acquisition of Tourmaline Bio, Inc. With the completion of the acquisition, shares of common stock, par...
Novartis announced that it has entered into a definitive agreement to acquire Avidity Biosciences, a San Diego-based biopharmaceutical company pioneering a new class of RNA-based...
Novartis announced the successful completion of its acquisition of Regulus Therapeutics, a clinical-stage biopharmaceutical company pioneering oligonucleotide therapies. With this milestone, Regulus becomes an...
Novartis announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Fabhalta (iptacopan), a first-in-class complement inhibitor for the reduction...
Dren Bio, Inc, a privately held, clinical-stage biopharmaceutical company developing antibody therapeutics for cancer, autoimmune, and other serious diseases, announced that it has entered...
